Karin Jirström

22.7k total citations · 3 hit papers
316 papers, 13.3k citations indexed

About

Karin Jirström is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Karin Jirström has authored 316 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Oncology, 121 papers in Molecular Biology and 95 papers in Cancer Research. Recurrent topics in Karin Jirström's work include Breast Cancer Treatment Studies (34 papers), Cancer Immunotherapy and Biomarkers (31 papers) and HER2/EGFR in Cancer Research (31 papers). Karin Jirström is often cited by papers focused on Breast Cancer Treatment Studies (34 papers), Cancer Immunotherapy and Biomarkers (31 papers) and HER2/EGFR in Cancer Research (31 papers). Karin Jirström collaborates with scholars based in Sweden, Ireland and United States. Karin Jirström's co-authors include Fredrik Pontén, Mathias Uhlén, Björn Nodin, Göran Landberg, Donal J. Brennan, Karin Leandersson, William M. Gallagher, Jakob Eberhard, Lisa Rydén and Signe Borgquist and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Karin Jirström

308 papers receiving 13.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

2011 1.3k citations David G. DeNardo, Donal J. Brennan et al. profile →
The Human Protein Atlas—a tool for pathology

2008 805 citations Karin Jirström, Mathias Uhlén et al. profile →
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients

2012 518 citations Karin Jirström, Karin Leandersson et al. BMC Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karin Jirström Sweden	59	6.2k	5.9k	3.9k	3.0k	2.1k	316	13.3k
Sunil Badve United States	59	6.4k 1.0×	5.5k 0.9×	4.6k 1.2×	1.3k 0.4×	2.0k 0.9×	309	14.3k
François Bertucci France	72	8.9k 1.4×	7.5k 1.3×	5.4k 1.4×	2.7k 0.9×	4.8k 2.3×	515	18.8k
Øystein Fodstad Norway	68	5.6k 0.9×	8.1k 1.4×	4.5k 1.2×	2.6k 0.9×	2.3k 1.1×	307	14.8k
Edi Brogi United States	55	5.6k 0.9×	6.0k 1.0×	5.4k 1.4×	1.5k 0.5×	2.1k 1.0×	237	15.8k
Thomas Kirchner Germany	63	8.1k 1.3×	7.4k 1.3×	3.7k 1.0×	1.5k 0.5×	2.4k 1.1×	271	15.2k
Dionyssios Katsaros Italy	61	4.6k 0.7×	7.1k 1.2×	4.5k 1.2×	2.8k 0.9×	1.0k 0.5×	200	13.7k
Peter M. Siegel Canada	53	7.0k 1.1×	9.0k 1.5×	3.6k 0.9×	1.7k 0.6×	1.6k 0.8×	148	14.7k
Christian Pilarsky Germany	55	5.2k 0.8×	8.0k 1.4×	4.4k 1.1×	1.5k 0.5×	1.6k 0.8×	188	12.9k
Kazuaki Takabe United States	60	4.3k 0.7×	7.0k 1.2×	2.8k 0.7×	2.1k 0.7×	2.3k 1.1×	398	12.6k
Celina G. Kleer United States	65	7.9k 1.3×	9.2k 1.6×	5.8k 1.5×	1.5k 0.5×	1.9k 0.9×	174	17.2k

Countries citing papers authored by Karin Jirström

Since Specialization

Citations

This map shows the geographic impact of Karin Jirström's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Jirström with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Jirström more than expected).

Fields of papers citing papers by Karin Jirström

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Jirström. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Jirström. The network helps show where Karin Jirström may publish in the future.

Co-authorship network of co-authors of Karin Jirström

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Jirström. A scholar is included among the top collaborators of Karin Jirström based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Jirström. Karin Jirström is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Viðarsdóttir, Halla, Karin Jirström, Björn Nodin, et al.. (2023). Diagnostic gastrointestinal markers in primary lung cancer and pulmonary metastases. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 485(2). 347–357. 2 indexed citations

Micke, Patrick, Johanna Sofia Margareta Mattsson, Linnéa La Fleur, et al.. (2020). Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non‐small cell lung cancer. Cancer Medicine. 9(15). 5609–5619. 9 indexed citations

Chandran, Vineesh Indira, Ann‐Sofie Månsson, Myriam Cerezo-Magaña, et al.. (2020). Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1. Molecular Cancer Research. 18(4). 644–656. 25 indexed citations

Bremer, Troy, Pat W. Whitworth, Rakesh Patel, et al.. (2018). A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. Clinical Cancer Research. 24(23). 5895–5901. 71 indexed citations

Elebro, Jacob, et al.. (2016). Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS ONE. 11(4). e0153533–e0153533. 20 indexed citations

Lundgren, Sebastian, Jacob Elebro, Margareta Heby, et al.. (2016). The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. PLoS ONE. 11(6). e0156497–e0156497. 28 indexed citations

Elebro, Karin, Signe Borgquist, Maria Simonsson, et al.. (2015). Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort. Clinical Cancer Research. 21(16). 3640–3650. 63 indexed citations

Bergenfelz, Caroline, Alexander Gaber, Roni Allaoui, et al.. (2015). S100A9 expressed in ER−PgR− breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. British Journal of Cancer. 113(8). 1234–1243. 28 indexed citations

Bjarnadottir, Olöf, Siker Kimbung, Karin Jirström, et al.. (2015). Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. Journal of Translational Medicine. 13(1). 133–133. 68 indexed citations

10.

Linke, Steven P., Troy Bremer, Pat W. Whitworth, et al.. (2015). Validation of a multi-marker test that predicts recurrence in patients diagnosed with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery (BCS). Cancer Research. 75(9). 1 indexed citations

11.

Zhou, Wenjing, Karin Jirström, Rose‐Marie Amini, et al.. (2013). Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer. 13(1). 512–512. 51 indexed citations

12.

Broselid, Stefan, Benxu Cheng, Martin Sjöström, et al.. (2013). G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients. Clinical Cancer Research. 19(7). 1681–1692. 35 indexed citations

13.

Harbst, Katja, Johan Staaf, Martin Lauss, et al.. (2012). Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research. 18(15). 4026–4036. 72 indexed citations

14.

Mulrane, Laoighse, Stephen F. Madden, Donal J. Brennan, et al.. (2012). miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro. Clinical Cancer Research. 18(24). 6702–6713. 71 indexed citations

15.

Coward, Jermaine, Hagen Kulbe, Probir Chakravarty, et al.. (2011). Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clinical Cancer Research. 17(18). 6083–6096. 313 indexed citations

16.

Buckley, Niamh E., Karin Jirström, Elaine W. Kay, et al.. (2011). The ΔNp63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer. Cancer Research. 71(5). 1933–1944. 34 indexed citations

17.

Rexhepaj, Elton, Karin Jirström, Darran P. O’Connor, et al.. (2010). Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer. 10(1). 639–639. 38 indexed citations

18.

Kovács, Anikó, Kristina Lövgren, Szilárd Nemes, et al.. (2010). Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. BMC Cancer. 10(1). 296–296. 30 indexed citations

19.

Ursini‐Siegel, Josie, Sean Cory, Dongmei Zuo, et al.. (2010). Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. Cancer Research. 70(20). 7776–7787. 24 indexed citations

20.

Larsson, Anna-Maria, Karin Jirström, Erik Fredlund, et al.. (2009). Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer. Clinical Cancer Research. 15(17). 5552–5559. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact